Search

Displaying results 4201 - 4210 of 9670 in total
  1. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    It is developed by MedImmune for the treatment of Allergic Rhinitis. … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.

  2. Drug

    Aspergillus repens

    go.drugbank.com/drugs/DB10449
    Approved

    Aspergillus repens is a fungus which can provoke allergic reactions. Aspergillus repens extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938
  3. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    It will be of major benefit to those patients not responding satisfactorily to diuretics alone. … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.

  4. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are...

  5. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    , regulatory T cells (Tregs), and conventional T cells (Tcons) — administered as sequential infusions. … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic

    International brands: ORCA-T
  6. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 inhibition of PAI-1, specifically, downregulates PCSK9 at the transcriptional level[A228793]. … TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,].

  7. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  8. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients. … The enzyme is a homotetramer consisted of 4 monomers with 629 amino acids, and holds the same amino acid sequence as human beta-glucuronidase (GUS) [FDA Label].

  9. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB. … [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

  10. Drug

    VB10.16

    go.drugbank.com/drugs/DB17512
    Investigational

    It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting